Speaker Profile

Chairman and CEO, ImpactNRS and Chairman, CEO, miR Scientific

Biography
Sam co-founded miR Scientific in 2014. Sam is a serial entrepreneur and a renowned executive who throughout his career held senior executive and board level positions developing game-changing technologies and companies across industries, including Biotech (president – Errant Gene Therapeutics), Art Authentication (CEO – Provenire Authentication), Aquaculture (Chairman – Greenfins Global) and Financial Services (Mission Markets Inc., a pioneering financial services firm focused on impact and sustainability markets.). Sam attended the American University of Paris in France and Macalester College in St. Paul, MN. He is a member of the Board of Trustees and Board of Selectors of the Jefferson Awards for Public Service.


Liquid Biopsy Showcase Showcase:

miR Scientific (www.mirscientific.com) is a precision bioscience company that has developed proprietary, non-invasive liquid biopsy urine tests that definitively detect, accurately score and continuously monitor prostate and bladder cancers.

miR Scientific Sentinel™️ PCa and CS Tests, Revolutionizing the Standard of Care Supporting Urologic Oncology
In the face of debilitating global prevalence and disease burden of urological cancer, miR has developed a urological oncology disease management platform that is centered around it’s proprietary non-invasive liquid biopsy urine tests. Based on profiling sncRNA isolated from Urinary Exosomes, the tests detect, score and continuously monitor prostate and bladder cancers with industry-leading accuracy. The presentation will show how the validated platform will comprehensively transform patient health outcomes and optimize the cost and availability of health service utilization.

 Session Abstract – PMWC Silicon Valley


The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).